# WIA-BIO-018: Bio-Ethics Specification v1.0

> **Standard ID:** WIA-BIO-018
> **Version:** 1.0.0
> **Published:** 2025-12-26
> **Status:** Active
> **Authors:** WIA Bioethics Research Group

---

## Table of Contents

1. [Introduction](#1-introduction)
2. [Ethical Principles](#2-ethical-principles)
3. [Informed Consent Framework](#3-informed-consent-framework)
4. [Institutional Review Board (IRB)](#4-institutional-review-board-irb)
5. [Vulnerable Populations](#5-vulnerable-populations)
6. [Genetic Data Ethics](#6-genetic-data-ethics)
7. [Gene Editing Ethics](#7-gene-editing-ethics)
8. [Implementation Guidelines](#8-implementation-guidelines)
9. [Safety and Compliance](#9-safety-and-compliance)
10. [References](#10-references)

---

## 1. Introduction

### 1.1 Purpose

This specification defines comprehensive ethical standards for biotechnology research, clinical applications, and genetic interventions, based on internationally recognized ethical principles and guidelines.

### 1.2 Scope

The standard covers:
- Ethical principles and frameworks
- Informed consent processes
- IRB review and approval
- Protection of vulnerable populations
- Genetic data privacy and governance
- Gene editing ethical considerations
- Compliance and monitoring

### 1.3 Philosophy

**弘益人間 (Benefit All Humanity)** - This standard ensures that biotechnology advances human welfare while protecting individual rights, promoting justice, and maintaining the integrity of scientific research.

### 1.4 Terminology

- **Informed Consent**: Voluntary agreement to participate based on adequate information
- **IRB**: Institutional Review Board responsible for ethical oversight
- **Vulnerable Population**: Groups requiring enhanced protection (children, prisoners, etc.)
- **Somatic Gene Editing**: Non-heritable genetic modifications
- **Germline Gene Editing**: Heritable genetic modifications affecting future generations
- **Minimal Risk**: Risk no greater than ordinary daily life or routine examination

---

## 2. Ethical Principles

### 2.1 The Belmont Report (1979)

Three fundamental ethical principles:

#### 2.1.1 Respect for Persons

**Principle**: Individuals should be treated as autonomous agents, and persons with diminished autonomy are entitled to protection.

**Implementation**:
```
Autonomy Score = (Voluntary × Information × Comprehension × Competence) / 4
```

Where each factor is rated 0-1:
- **Voluntary**: Free from coercion or undue influence
- **Information**: Adequate disclosure of relevant facts
- **Comprehension**: Understanding of disclosed information
- **Competence**: Capacity to make informed decisions

**Requirements**:
- Obtain informed consent before any research intervention
- Protect those with reduced autonomy (children, cognitively impaired)
- Allow withdrawal at any time without penalty
- Respect privacy and confidentiality

#### 2.1.2 Beneficence

**Principle**: Maximize benefits and minimize potential harms.

**Risk-Benefit Calculation**:
```
Benefit-Risk Ratio = (Expected Benefits) / (Potential Risks + Uncertainty Factor)
```

**Requirements**:
- Design research to maximize knowledge and minimize risk
- Ensure benefits outweigh risks
- Monitor for adverse events
- Provide best available interventions

**Benefit Categories**:
1. Direct benefit to participant
2. Generalizable knowledge
3. Societal benefit
4. Scientific advancement

**Risk Categories**:
1. Physical harm (injury, illness, death)
2. Psychological harm (stress, trauma)
3. Social harm (stigma, discrimination)
4. Economic harm (cost, lost wages)

#### 2.1.3 Justice

**Principle**: Fair distribution of research burdens and benefits.

**Justice Equation**:
```
Justice Score = 1 - |Population Risk Share - Population Benefit Share|
```

**Requirements**:
- Equitable selection of research participants
- Avoid exploitation of vulnerable populations
- Ensure access to benefits for those who bore risks
- Prevent discrimination in participant selection

### 2.2 Declaration of Helsinki (1964, revised 2013)

**Core Principles**:
1. **Primacy of participant welfare** over science and society
2. **Scientific validity** as ethical requirement
3. **Independent ethical review** by IRB
4. **Physician oversight** for medical research
5. **Privacy and confidentiality** protection
6. **Post-trial access** to beneficial interventions

### 2.3 Four Pillars of Clinical Bioethics

#### 2.3.1 Autonomy
- Informed consent
- Truth-telling
- Confidentiality
- Respect for patient decisions

#### 2.3.2 Beneficence
- Provide benefits
- Promote well-being
- Prevent harm
- Remove harm

#### 2.3.3 Non-Maleficence
- "First, do no harm" (Primum non nocere)
- Avoid causing harm
- Minimize unavoidable harm
- Proportionality of harm to benefit

#### 2.3.4 Justice
- Fair allocation of resources
- Equitable access to care
- Non-discrimination
- Respect for rights

---

## 3. Informed Consent Framework

### 3.1 Essential Elements

Required components of informed consent:

#### 3.1.1 Information Disclosure

**Must include**:
1. **Research purpose** and procedures
2. **Duration** of participation
3. **Risks** (physical, psychological, social, economic)
4. **Benefits** (direct and indirect)
5. **Alternatives** to participation
6. **Confidentiality** measures
7. **Compensation** for injury
8. **Voluntary participation** and right to withdraw
9. **Contact information** for questions
10. **Future use** of data/samples

**Risk Disclosure Formula**:
```
Risk_Disclosure_Adequacy = Σ(Risk_i × Probability_i × Severity_i) / Total_Risks
```

#### 3.1.2 Comprehension

**Assessment Methods**:
- Teach-back method: Ask participant to explain in own words
- Quiz or questionnaire: Test understanding of key points
- Comprehension score: Must achieve ≥80% to proceed

**Comprehension Formula**:
```
Comprehension = (Correct_Responses / Total_Questions) × 100
Minimum_Required = 80%
```

#### 3.1.3 Voluntariness

**Coercion Indicators** (must be absent):
- Explicit threats or pressure
- Excessive incentives
- Exploitation of authority relationships
- Time pressure or urgency tactics
- Withholding of standard care

**Voluntariness Score**:
```
V = 1 - (Coercion_Indicators / Maximum_Indicators)
V ≥ 0.95 required for valid consent
```

#### 3.1.4 Competence

**Capacity Assessment**:
- Understanding: Can explain research
- Appreciation: Recognizes personal relevance
- Reasoning: Can weigh options logically
- Choice: Can express clear decision

**Capacity Determination**:
```
Capacity = (Understanding + Appreciation + Reasoning + Choice) / 4
Capacity ≥ 0.75 required for autonomous consent
```

For participants with Capacity < 0.75:
- Require legally authorized representative (LAR)
- Seek assent if possible (children, mild impairment)
- Enhanced monitoring and protection

### 3.2 Consent Documentation

#### 3.2.1 Required Signatures

**Primary**:
- Participant (or legally authorized representative)
- Date and time
- Witness (for vulnerable populations or illiterate participants)

**Secondary**:
- Person obtaining consent
- Principal investigator (for high-risk studies)
- IRB approval stamp/signature

#### 3.2.2 Document Retention

- Original: Keep with research records
- Copy: Provide to participant
- Duration: Minimum 7 years after study completion
- Access: Available for audit by IRB, sponsors, regulatory agencies

### 3.3 Special Consent Situations

#### 3.3.1 Waiver of Consent

Permitted only when:
1. Research poses minimal risk
2. Waiver will not adversely affect rights/welfare
3. Research impracticable without waiver
4. Participants will be provided pertinent information afterward

#### 3.3.2 Emergency Research Exception

Requirements:
- Life-threatening condition
- Intervention must be tested in emergency
- Cannot obtain consent from participant or LAR
- Community consultation conducted
- Public disclosure of research
- Independent data monitoring
- Informed consent sought from participant or LAR at earliest opportunity

---

## 4. Institutional Review Board (IRB)

### 4.1 Composition

**Minimum Requirements**:
- At least 5 members
- Diverse in race, gender, cultural background
- Scientific and non-scientific members
- Community representative (non-affiliated)
- Expertise relevant to research

**Prohibited**:
- Conflict of interest
- Reviewing own research
- Institutional pressure to approve

### 4.2 Review Criteria

IRB must determine that:

1. **Risks minimized** through sound research design
2. **Risks reasonable** relative to benefits
3. **Selection equitable**
4. **Informed consent** obtained and documented
5. **Data monitoring** plan adequate
6. **Privacy and confidentiality** protected
7. **Vulnerable populations** appropriately protected

### 4.3 Review Levels

#### 4.3.1 Exempt Review

**Criteria**:
- Minimal risk
- Educational research
- Anonymous surveys
- Observation of public behavior
- Analysis of existing de-identified data

**Process**: Administrative review by IRB chair or designee

#### 4.3.2 Expedited Review

**Criteria**:
- Minimal risk
- Minor changes to approved protocols
- Collection of: blood samples, voice recordings, data through non-invasive procedures

**Process**: Review by IRB chair or experienced reviewer(s)

#### 4.3.3 Full Board Review

**Required for**:
- Greater than minimal risk
- Vulnerable populations
- Novel interventions
- Controversial research

**Process**:
- Quorum: Majority of members
- Non-scientist present
- Community member present
- Vote: Majority approval required
- Meeting frequency: At least monthly

### 4.4 Continuing Review

**Frequency**:
- At least annually
- More frequently for high-risk studies
- For adverse events or protocol deviations

**Requirements**:
- Progress reports
- Adverse event summaries
- Updated consent forms
- Protocol amendments
- Re-approval before continuation

### 4.5 Adverse Event Reporting

**Timelines**:
```
Severity Level         Reporting Deadline
----------------------------------------
Fatal/Life-threatening  24 hours
Serious                 7 days
Unexpected             15 days
Other                  30 days
```

**Report Must Include**:
- Participant ID (de-identified)
- Event description
- Severity and outcome
- Causality assessment
- Actions taken
- Protocol modifications

---

## 5. Vulnerable Populations

### 5.1 Children

**Definition**: Persons under 18 years (or age of majority in jurisdiction)

**Enhanced Protections**:
1. **Parental Permission**: Both parents when feasible
2. **Child Assent**: For children ≥7 years
3. **Risk Limits**: Minimal risk or minor increase over minimal risk
4. **Benefit Requirement**: Prospect of direct benefit or generalizable knowledge

**Risk Categories**:
```
Category 1: Minimal risk
Category 2: Minor increase over minimal risk with prospect of direct benefit
Category 3: Minor increase over minimal risk, no direct benefit, but vital knowledge
Category 4: Not otherwise approvable, but opportunity to prevent/treat condition
```

**Assent Requirements**:
- Age-appropriate explanation
- Opportunity to ask questions
- Freedom to decline
- Respect for dissent (unless intervention offers direct benefit)

### 5.2 Pregnant Women and Fetuses

**Enhanced Protections**:
1. **Preclinical Studies**: Animal studies on reproductive toxicity
2. **Risk to Fetus**: Minimize and disclose
3. **Consent**: Father's consent when feasible (unless pregnancy resulted from rape/incest)
4. **Purpose**: Benefit to woman, fetus, or knowledge about pregnancy/neonatal conditions
5. **No Incentives**: To terminate or continue pregnancy

**Acceptable Research**:
- Minimal risk to fetus
- Risk justified by benefit to woman or fetus
- Knowledge cannot be obtained by other means

### 5.3 Prisoners

**Enhanced Protections**:
1. **IRB Composition**: Prisoner or prisoner representative required
2. **Purpose**: Study of prisons, prisoners, or conditions affecting prisoners
3. **Risk**: Minimal risk only (with exceptions for beneficial interventions)
4. **Voluntariness**: Enhanced monitoring for coercion
5. **No Advantage**: Participation cannot affect parole decisions

**Prohibited**:
- Research on practices aimed at rehabilitation
- Cosmetic or convenience studies
- Most pharmaceutical research (unless benefits prisoners as class)

### 5.4 Cognitively Impaired Persons

**Enhanced Protections**:
1. **Capacity Assessment**: Formal evaluation
2. **LAR Consent**: Legally authorized representative
3. **Assent**: Seek participant assent when possible
4. **Monitor**: Respect for dissent
5. **Re-evaluation**: Periodic capacity reassessment

**Capacity Levels**:
```
Full Capacity (1.0)       - Independent consent
Borderline (0.75-0.99)    - Independent with support
Diminished (0.50-0.74)    - LAR with participant assent
Severely Impaired (<0.50) - LAR decision, seek assent
```

### 5.5 Economically/Educationally Disadvantaged

**Protections Against Exploitation**:
1. **Equitable Selection**: Not chosen solely for convenience
2. **Reasonable Compensation**: Not undue inducement
3. **Benefit Sharing**: Access to research results/interventions
4. **Cultural Sensitivity**: Language, literacy, beliefs
5. **Community Engagement**: Involve community in research design

---

## 6. Genetic Data Ethics

### 6.1 Privacy and Confidentiality

**Data Protection Levels**:

```
Level 1: Anonymous - No identifiers, cannot re-identify
Level 2: De-identified - Coded, can re-identify with key
Level 3: Confidential - Identified but protected
Level 4: Public - Openly shared
```

**Required Protection**:
- Encryption: AES-256 minimum
- Access Control: Role-based, audit logs
- Storage: Secure servers, off-site backup
- Transmission: Encrypted channels only
- De-identification: Remove 18 HIPAA identifiers

### 6.2 Genetic Discrimination Protection

**Prohibited Uses**:
1. Employment discrimination based on genetic information
2. Health insurance discrimination
3. Life insurance discrimination (varies by jurisdiction)
4. Educational discrimination
5. Social stigmatization

**Legal Frameworks**:
- GINA (Genetic Information Nondiscrimination Act, US)
- GDPR (General Data Protection Regulation, EU)
- Local genetic privacy laws

### 6.3 Incidental Findings

**Definition**: Clinically significant findings beyond research scope

**Management Protocol**:
1. **Pre-study Disclosure**: Inform participants of possibility
2. **Return Policy**: Specify what will/won't be returned
3. **Clinical Confirmation**: Verify findings in clinical lab
4. **Genetic Counseling**: Provide for significant findings
5. **Family Implications**: Discuss implications for relatives

**Return Criteria**:
```
Should Return if:
- Clinically significant
- Actionable (treatment/prevention available)
- High validity (confirmed)
- Participant wants to know

May Return if:
- Significant but not actionable
- Uncertain significance
- Participant specifically requested

Should Not Return:
- Non-actionable
- Low validity
- Participant declined to know
```

### 6.4 Secondary Use of Data

**Requirements**:
1. **Original Consent**: Covered secondary use
2. **IRB Approval**: For new research questions
3. **De-identification**: When possible
4. **Purpose Limitation**: Aligned with original consent
5. **Re-contact**: If consent doesn't cover new use

---

## 7. Gene Editing Ethics

### 7.1 Somatic vs. Germline Editing

**Comparison**:

| Aspect | Somatic | Germline |
|--------|---------|----------|
| Target | Body cells | Reproductive cells, embryos |
| Heritability | Not inherited | Inherited by offspring |
| Ethical Status | Generally acceptable | Controversial/restricted |
| Current Use | Clinical trials | Research only (most jurisdictions) |
| Reversibility | Limited to individual | Irreversible for lineage |

### 7.2 Somatic Gene Editing Ethics

**Acceptable When**:
1. **Therapeutic Purpose**: Treat or prevent disease
2. **Favorable Risk-Benefit**: Benefits outweigh risks
3. **No Alternatives**: Conventional treatments inadequate
4. **Informed Consent**: Full disclosure of risks/benefits
5. **Scientific Validity**: Strong preclinical evidence
6. **Long-term Monitoring**: Track safety and efficacy

**Ethical Concerns**:
- **Off-target Effects**: Unintended genetic changes
- **Immune Responses**: Rejection of edited cells
- **Mosaicism**: Incomplete editing
- **Long-term Effects**: Unknown consequences
- **Access**: Equitable availability

**Risk Assessment**:
```
Somatic_Risk_Score = (
  Off_Target_Probability × Severity +
  Immune_Risk × Severity +
  Unknown_Effects × Uncertainty
) / Normalization_Factor

Acceptable if: Risk_Score < Benefit_Score
```

### 7.3 Germline Gene Editing Ethics

**Current Consensus**: Moratorium on clinical applications

**Ethical Arguments AGAINST**:
1. **Unknown Risks**: Long-term, multi-generational effects unknown
2. **No Consent**: Future generations cannot consent
3. **Irreversibility**: Cannot undo for descendants
4. **Enhancement**: Slippery slope to non-therapeutic uses
5. **Justice**: Exacerbate inequalities
6. **Eugenics**: Historical concerns about genetic "improvement"

**Ethical Arguments FOR** (limited cases):
1. **Prevent Suffering**: Eliminate severe genetic diseases
2. **Family Choice**: Reproductive autonomy
3. **Scientific Progress**: Advance understanding
4. **Global Health**: Reduce disease burden

**Potential Acceptable Use Cases**:
- **Serious Genetic Disease**: No other options
- **Proven Safety**: Extensive preclinical evidence
- **International Consensus**: Global agreement
- **Robust Oversight**: Rigorous regulatory framework
- **Therapeutic Only**: No enhancement

**Prohibited Uses**:
- Enhancement of normal traits
- Sex selection for non-medical reasons
- Cosmetic modifications
- Performance enhancement
- Intelligence augmentation

### 7.4 Gene Editing Decision Framework

**Ethical Evaluation Process**:

```
Step 1: Classify Intervention
  - Somatic or Germline?
  - Therapeutic or Enhancement?
  - Serious disease or minor condition?

Step 2: Assess Scientific Validity
  - Preclinical evidence?
  - Mechanism understood?
  - Safety demonstrated?

Step 3: Evaluate Risk-Benefit
  - Benefits to individual?
  - Risks acceptable?
  - Alternatives available?

Step 4: Consider Justice
  - Equitable access?
  - Vulnerable populations protected?
  - Global implications?

Step 5: Ensure Oversight
  - IRB approval?
  - Regulatory compliance?
  - Public engagement?

Step 6: Obtain Consent
  - Informed consent?
  - Capacity confirmed?
  - Voluntariness assured?

Decision:
  Proceed if: All steps satisfied AND Benefits > Risks
  Defer if: Uncertainty too high
  Reject if: Ethical principles violated
```

---

## 8. Implementation Guidelines

### 8.1 Required Components

Any WIA-BIO-018 compliant system must include:

1. **Consent Management**: Digital consent capture and tracking
2. **IRB Submission**: Protocol preparation and submission
3. **Risk Assessment**: Automated ethical risk evaluation
4. **Privacy Protection**: Data security and de-identification
5. **Audit Trail**: Complete record of ethical decisions
6. **Reporting**: Adverse event and progress reporting

### 8.2 API Interface

#### 8.2.1 Validate Informed Consent

```typescript
interface ConsentValidation {
  participantId: string;
  studyId: string;
  consentForm: {
    voluntaryParticipation: boolean;
    risksDisclosed: boolean;
    benefitsExplained: boolean;
    alternativesProvided: boolean;
    withdrawalRights: boolean;
    privacyProtection: boolean;
  };
  comprehensionScore?: number;
  witnessPresent: boolean;
  signature: {
    participant: boolean;
    witness?: boolean;
    date: Date;
  };
}

interface ConsentResult {
  isValid: boolean;
  complianceScore: number;
  violations: string[];
  warnings: string[];
  recommendations: string[];
}
```

#### 8.2.2 Assess Ethical Risk

```typescript
interface RiskAssessment {
  studyType: string;
  targetPopulation: 'adults' | 'children' | 'pregnant-women' | 'prisoners' | 'cognitively-impaired';
  interventionType: 'observational' | 'drug' | 'device' | 'behavioral' | 'gene-therapy';
  potentialBenefits: string[];
  potentialRisks: string[];
  riskLevel: 'minimal' | 'minor-increase' | 'greater-than-minimal';
}

interface RiskResult {
  ethicalScore: number;
  riskBenefitRatio: number;
  recommendation: 'approve' | 'revise' | 'reject';
  requiredProtections: string[];
}
```

#### 8.2.3 Submit IRB Protocol

```typescript
interface IRBProtocol {
  title: string;
  principalInvestigator: string;
  institution: string;
  studyType: string;
  objectives: string;
  methodology: string;
  participants: {
    targetPopulation: string;
    sampleSize: number;
    inclusionCriteria: string[];
    exclusionCriteria: string[];
  };
  risks: string[];
  benefits: string[];
  consentProcess: string;
  dataManagement: string;
}

interface IRBSubmission {
  submissionId: string;
  status: 'submitted' | 'under-review' | 'approved' | 'rejected' | 'revisions-required';
  reviewLevel: 'exempt' | 'expedited' | 'full-board';
  reviewDate?: Date;
  decision?: string;
}
```

### 8.3 Data Formats

#### 8.3.1 Consent Record

```json
{
  "consentId": "CONSENT-2025-001",
  "participantId": "P-12345",
  "studyId": "STUDY-2025-CANCER",
  "consentDate": "2025-12-26T10:30:00Z",
  "version": "3.1",
  "language": "en",
  "elements": {
    "purpose": true,
    "procedures": true,
    "duration": true,
    "risks": true,
    "benefits": true,
    "alternatives": true,
    "confidentiality": true,
    "compensation": true,
    "voluntary": true,
    "withdrawal": true,
    "contact": true
  },
  "comprehension": {
    "score": 0.92,
    "method": "teach-back",
    "assessor": "RN-001"
  },
  "signatures": {
    "participant": {
      "signed": true,
      "date": "2025-12-26T10:30:00Z",
      "method": "digital"
    },
    "witness": {
      "signed": true,
      "name": "Jane Smith",
      "date": "2025-12-26T10:30:00Z"
    },
    "investigator": {
      "signed": true,
      "name": "Dr. John Doe",
      "date": "2025-12-26T10:35:00Z"
    }
  },
  "validity": {
    "isValid": true,
    "complianceScore": 0.98
  }
}
```

### 8.4 Error Handling

Standard error codes:

| Code | Meaning | Action |
|------|---------|--------|
| E001 | Incomplete consent | Complete all required elements |
| E002 | Insufficient comprehension | Re-educate and reassess |
| E003 | Coercion detected | Remove pressure, allow time |
| E004 | Capacity concerns | Obtain LAR consent |
| E005 | IRB approval required | Submit protocol for review |
| E006 | Privacy violation | Enhance data protection |

---

## 9. Safety and Compliance

### 9.1 Pre-Study Checklist

- [ ] IRB approval obtained
- [ ] Informed consent form approved
- [ ] Consent process documented
- [ ] Data security plan implemented
- [ ] Adverse event reporting plan established
- [ ] Staff training completed
- [ ] Vulnerable population protections in place
- [ ] Risk-benefit analysis documented

### 9.2 Monitoring Requirements

**Continuous Monitoring**:
1. **Consent Quality**: Review sample of consents monthly
2. **Adverse Events**: Real-time reporting
3. **Protocol Compliance**: Quarterly audits
4. **Data Security**: Continuous monitoring
5. **Participant Satisfaction**: Semi-annual surveys

### 9.3 Audit and Inspection

**Internal Audits**: Quarterly
**External Audits**: Annually or as required by sponsors/regulators

**Audit Scope**:
- Informed consent documentation
- IRB correspondence
- Protocol adherence
- Data integrity
- Safety reporting
- Regulatory compliance

### 9.4 Regulatory Compliance

**Key Regulations**:
- **45 CFR 46** (Common Rule, US)
- **21 CFR 50, 56** (FDA regulations, US)
- **ICH-GCP** (International Council for Harmonisation)
- **GDPR** (EU data protection)
- **Local regulations** (country-specific)

---

## 10. References

### 10.1 Foundational Documents

1. The Belmont Report (1979) - US Department of Health and Human Services
2. Declaration of Helsinki (2013) - World Medical Association
3. The Nuremberg Code (1947) - Trials of War Criminals
4. ICH-GCP E6(R2) (2016) - International Council for Harmonisation
5. CIOMS International Ethical Guidelines (2016) - Council for International Organizations of Medical Sciences

### 10.2 Regulations

| Region | Regulation | Description |
|--------|------------|-------------|
| US | 45 CFR 46 | Common Rule for human subjects protection |
| US | 21 CFR 50, 56 | FDA regulations for consent and IRB |
| US | HIPAA | Health information privacy |
| US | GINA | Genetic information nondiscrimination |
| EU | GDPR | General Data Protection Regulation |
| EU | Clinical Trials Regulation | EU CTR 536/2014 |
| International | ICH-GCP | Good Clinical Practice |

### 10.3 WIA Standards

- WIA-INTENT: Intent-based interfaces
- WIA-OMNI-API: Universal API gateway
- WIA-SOCIAL: Social coordination protocols
- WIA-BIO-002: Genetic Testing standards
- WIA-BIO-005: CRISPR-Cas9 standards

---

## Appendix A: Example Risk-Benefit Analysis

### A.1 Gene Therapy for Sickle Cell Disease

```
Study: CRISPR-based gene editing for sickle cell disease

Potential Benefits:
- Cure for severe genetic disease (weight: 10)
- Improved quality of life (weight: 8)
- Reduced healthcare burden (weight: 6)
- Generalizable knowledge (weight: 4)
Total Benefit Score: 28

Potential Risks:
- Off-target effects (probability: 0.05, severity: 8) = 0.4
- Immune response (probability: 0.1, severity: 6) = 0.6
- Treatment failure (probability: 0.2, severity: 4) = 0.8
- Long-term unknown (probability: 0.3, severity: 5) = 1.5
Total Risk Score: 3.3

Risk-Benefit Ratio: 28 / 3.3 = 8.5

Conclusion: Favorable risk-benefit profile
Recommendation: APPROVE with enhanced monitoring
```

### A.2 Consent Comprehension Assessment

```
Participant: P-67890
Study: Diabetes Drug Trial

Questions Asked:
1. What is the purpose of this study? ✓ Correct
2. How long will you participate? ✓ Correct
3. What are the main risks? ✓ Correct
4. Can you stop at any time? ✓ Correct
5. What are the alternatives? ✗ Incorrect
6. Who will see your data? ✓ Correct
7. Will you be compensated? ✓ Correct
8. How will privacy be protected? ✓ Correct
9. What happens if you're injured? ✗ Incorrect
10. Who can you contact with questions? ✓ Correct

Score: 8/10 = 80%
Result: PASS (minimum 80% required)
Action: Clarify questions 5 and 9, re-assess
```

---

**弘益人間 (홍익인간) · Benefit All Humanity**

*WIA-BIO-018 Specification v1.0*
*© 2025 SmileStory Inc. / WIA*
*MIT License*
